Search

Displaying results 3861 - 3870 of 7059 in total
  1. Drug

    Sitofibrate

    go.drugbank.com/drugs/DB21192
    Experimental

    Sitofibrate has a monoisotopic molecular weight of 610.42 Da. … Sitofibrate is a small molecule drug.

  2. Drug

    Ninerafaxstat

    go.drugbank.com/drugs/DB21486
    Investigational

    Ninerafaxstat has a monoisotopic molecular weight of 415.21 Da. … Ninerafaxstat is a small molecule drug.

  3. Drug

    Ebaresdax

    go.drugbank.com/drugs/DB21496
    Investigational

    Ebaresdax has a monoisotopic molecular weight of 266.07 Da. … Ebaresdax is a small molecule drug.

  4. Drug

    Razpipadon

    go.drugbank.com/drugs/DB21542
    Investigational

    Razpipadon has a monoisotopic molecular weight of 389.12 Da. … Razpipadon is a small molecule drug.

  5. Drug

    Zatonacaftor

    go.drugbank.com/drugs/DB21625
    Experimental

    Zatonacaftor has a monoisotopic molecular weight of 453.17 Da. … Zatonacaftor is a small molecule drug.

  6. Drug

    N-acetyltyrosine

    go.drugbank.com/drugs/DB11102
    ApprovedInvestigational

    N-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor. [DB00135] is a non-essential amino acid with a polar side group. … It is typically administered as a source of nutritional support where oral nutrition is inadequate or cannot be tolerated.

    Synonyms: Melanowhite-A
  7. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test. … Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor.

  8. Drug

    Insulin degludec

    go.drugbank.com/drugs/DB09564
    ApprovedInvestigational

    [A18561,A18562,A18563,A18564,A174934] Marketed as the brand name product Tresiba, insulin degludec has a duration of action up to 42 hours allowing for once-daily dosing, typically at bedtime. … of basal insulin over 42 hours with a low peak: trough ratio.

  9. Drug

    Tofersen

    go.drugbank.com/drugs/DB14782
    ApprovedInvestigational

    [A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation. … [L46133] Continual FDA approval is contingent on clinical benefits from ongoing trials, particularly the Phase 3 ATLAST study in people with presymptomatic SOD1-ALS.

    Synonyms: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP
  10. Drug

    Islatravir

    go.drugbank.com/drugs/DB15653
    ApprovedInvestigational

    [A275492, L56138] Chemically, it is a deoxyadenosine analogue distinguished by a 4'-ethynyl group and a 2-fluoro substitution, which collectively enhance its metabolic stability and potency. … adults who are virologically suppressed on a stable antiretroviral regimen.